在AL氨基粉症的分子景观
Tal Zvida-Bloch1,2, Eli Muchtar3, Angela Dispenzieri3
1Department of Molecular Biology, Faculty of Natural Sciences, Ariel University, Ariel, Israel.
British journal of haematology
|April 11, 2025
概括
粉样蛋白轻链粉样症涉及错误折叠的蛋白质,导致器官损伤. 了解其遗传和分子基础是开发向治疗和改善患者治疗结果的关键.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
背景情况:
- 粉样蛋白轻链 (AL) 粉样蛋白症是一种血细胞疾病,由于免疫球蛋白轻链错误折叠,导致器官功能障碍.
- 由于复杂的分子机制和多种器官参与,该疾病带来了诊断和治疗方面的挑战.
研究的目的:
- 审查AL氨基粉症的分子格局,重点关注遗传,转录和蛋白质变化.
- 突出多层次分析对于了解病原和推进精准医学的重要性.
主要方法:
- 对AL氨基粉症的遗传,转录和蛋白质基因变异现有文献的综述.
- 分析导致粉素轻链产生,不稳定和沉积的因素.
主要成果:
- 确定了关键的分子变化,包括染色体异常,体质突变和异常基因表达.
- 突出了受损的蛋白质折叠通路和细胞因子/化学因子分泌在疾病进展中的作用.
- 指出,这些因素导致器官特异性沉积,临床异质性和可变结果.
结论:
- 整合DNA,RNA和蛋白质分析对于更深入地了解AL氨基粉症的发病过程至关重要.
- 开发有效的临床前模型和识别生物标志物对于个性化疗法至关重要.
- 增强的分子洞察力对于改善AL氨基粉症的诊断,预后和治疗策略至关重要.
更多相关视频
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
10.5K
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015
8.7K
相关概念视频
Amyloid Fibrils
5.1K
5.1K
Alzheimer's Disease: Overview
358
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
358
